Chimeric Hemagglutinin-Based Live-Attenuated Vaccines Confer Durable Protective Immunity Against Influenza A Viruses in a Preclinical Ferret Model

Overview

Journal Vaccines (Basel)

Date 2021 Jan 14

PMID 33440898

Citations 13

Authors

Wen-Chun Liu

Raffael Nachbagauer

Daniel Stadlbauer

Shirin Strohmeier

Alicia Solorzano

Francesco Berlanda-Scorza

Bruce L Innis

Adolfo Garcia-Sastre

Peter Palese

Florian Krammer

Randy A Albrecht

Affiliations

Soon will be listed here.

Abstract

Epidemic or pandemic influenza can annually cause significant morbidity and mortality in humans. We developed novel chimeric hemagglutinin (cHA)-based universal influenza virus vaccines, which contain a conserved HA stalk domain from a 2009 pandemic H1N1 (pH1N1) strain combined with globular head domains from avian influenza A viruses. Our previous reports demonstrated that prime-boost sequential immunizations induced robust antibody responses directed toward the conserved HA stalk domain in ferrets. Herein, we further followed vaccinated animals for one year to compare the efficacy and durability of these vaccines in the preclinical ferret model of influenza. Although all cHA-based immunization regimens induced durable HA stalk-specific and heterosubtypic antibody responses in ferrets, sequential immunization with live-attenuated influenza virus vaccines (LAIV-LAIV) conferred the best protection against upper respiratory tract infection by a pH1N1 influenza A virus. The findings from this study suggest that our sequential immunization strategy for a cHA-based universal influenza virus vaccine provides durable protective humoral and cellular immunity against influenza virus infection.

Citing Articles

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity.

Rathnasinghe R, Chang L, Pearl R, Jangra S, Aspelund A, Hoag A NPJ Vaccines. 2024; 9(1):169.

PMID: 39300090 PMC: 11413010. DOI: 10.1038/s41541-024-00952-7.

Disulfide-stabilized trimeric hemagglutinin ectodomains provide enhanced heterologous influenza protection.

Liu D, Zhong X, Ru Y, Zhao S, Liu C, Tang Y Emerg Microbes Infect. 2024; 13(1):2389095.

PMID: 39101691 PMC: 11334750. DOI: 10.1080/22221751.2024.2389095.

Protective efficacy of a universal influenza mRNA vaccine against the challenge of H1 and H5 influenza A viruses in mice.

Li Y, Wang X, Zeng X, Ren W, Liao P, Zhu B mLife. 2024; 2(3):308-316.

PMID: 38817814 PMC: 10989953. DOI: 10.1002/mlf2.12085.

Immunogenicity of chimeric hemagglutinins delivered by an orf virus vector platform against swine influenza virus.

do Nascimento G, de Oliveira P, Butt S, Diel D Front Immunol. 2024; 15:1322879.

PMID: 38482020 PMC: 10933025. DOI: 10.3389/fimmu.2024.1322879.

Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.

Puente-Massaguer E, Vasilev K, Beyer A, Loganathan M, Francis B, Scherm M Sci Adv. 2023; 9(37):eadi4753.

PMID: 37703367 PMC: 10499326. DOI: 10.1126/sciadv.adi4753.

References

Nachbagauer R, Feser J, Naficy A, Bernstein D, Guptill J, Walter E . A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat Med. 2020; 27(1):106-114. DOI: 10.1038/s41591-020-1118-7. View

Isakova-Sivak I, Matyushenko V, Kotomina T, Kiseleva I, Krutikova E, Donina S . Sequential Immunization with Universal Live Attenuated Influenza Vaccine Candidates Protects Ferrets against a High-Dose Heterologous Virus Challenge. Vaccines (Basel). 2019; 7(3). PMC: 6789596. DOI: 10.3390/vaccines7030061. View

Iuliano A, Roguski K, Chang H, Muscatello D, Palekar R, Tempia S . Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2017; 391(10127):1285-1300. PMC: 5935243. DOI: 10.1016/S0140-6736(17)33293-2. View

Krammer F, Pica N, Hai R, Margine I, Palese P . Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013; 87(12):6542-50. PMC: 3676110. DOI: 10.1128/JVI.00641-13. View

Nachbagauer R, Kinzler D, Choi A, Hirsh A, Beaulieu E, Lecrenier N . A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines. 2017; 1. PMC: 5707880. DOI: 10.1038/npjvaccines.2016.15. View

Liu W, Nachbagauer R, Krammer F, Albrecht R . Assessment of Influenza Virus Hemagglutinin Stalk-Specific Antibody Responses. Methods Mol Biol. 2018; 1836:487-511. DOI: 10.1007/978-1-4939-8678-1_23. View

Jansen J, Gerlach T, Elbahesh H, Rimmelzwaan G, Saletti G . Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J Clin Virol. 2019; 119:44-52. DOI: 10.1016/j.jcv.2019.08.009. View

Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A . Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol. 2017; 18(4):464-473. PMC: 5360498. DOI: 10.1038/ni.3684. View

Liu W, Nachbagauer R, Stadlbauer D, Solorzano A, Berlanda-Scorza F, Garcia-Sastre A . Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Front Immunol. 2019; 10:756. PMC: 6499175. DOI: 10.3389/fimmu.2019.00756. View

10.

Petrie J, Ohmit S, Truscon R, Johnson E, Braun T, Levine M . Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season. J Infect Dis. 2016; 214(8):1142-9. DOI: 10.1093/infdis/jiw105. View

11.

Belser J, Eckert A, Tumpey T, Maines T . Complexities in Ferret Influenza Virus Pathogenesis and Transmission Models. Microbiol Mol Biol Rev. 2016; 80(3):733-44. PMC: 4981671. DOI: 10.1128/MMBR.00022-16. View

12.

Yan L, Li O, Poh C, Perera R, Valkenburg S, Peiris M . Combined use of live-attenuated and inactivated influenza vaccines to enhance heterosubtypic protection. Virology. 2018; 525:73-82. PMC: 6275109. DOI: 10.1016/j.virol.2018.09.007. View

13.

Houser K, Subbarao K . Influenza vaccines: challenges and solutions. Cell Host Microbe. 2015; 17(3):295-300. PMC: 4362519. DOI: 10.1016/j.chom.2015.02.012. View

14.

Puig-Barbera J, Mira-Iglesias A, Tortajada-Girbes M, Lopez-Labrador F, Librero-Lopez J, Diez-Domingo J . Waning protection of influenza vaccination during four influenza seasons, 2011/2012 to 2014/2015. Vaccine. 2017; 35(43):5799-5807. DOI: 10.1016/j.vaccine.2017.09.035. View

15.

Elbahesh H, Saletti G, Gerlach T, Rimmelzwaan G . Broadly protective influenza vaccines: design and production platforms. Curr Opin Virol. 2018; 34:1-9. DOI: 10.1016/j.coviro.2018.11.005. View

16.

Erbelding E, Post D, Stemmy E, Roberts P, Augustine A, Ferguson S . A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018; 218(3):347-354. PMC: 6279170. DOI: 10.1093/infdis/jiy103. View

17.

Yamayoshi S, Kawaoka Y . Current and future influenza vaccines. Nat Med. 2019; 25(2):212-220. DOI: 10.1038/s41591-018-0340-z. View

18.

Ortiz J, Hickling J, Jones R, Donabedian A, Engelhardt O, Katz J . Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016. Vaccine. 2017; 36(7):932-938. DOI: 10.1016/j.vaccine.2017.11.061. View

19.

Xu X, Blanton L, Abd Elal A, Alabi N, Barnes J, Biggerstaff M . Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine. MMWR Morb Mortal Wkly Rep. 2019; 68(24):544-551. PMC: 6586370. DOI: 10.15585/mmwr.mm6824a3. View

20.

Hampson A, Barr I, Cox N, Donis R, Siddhivinayak H, Jernigan D . Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015. Vaccine. 2017; 35(8):1104-1109. PMC: 5357705. DOI: 10.1016/j.vaccine.2017.01.018. View